Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine 2023;389:514-526.
What it found
Primary endpoint at 24 weeks: -7.2% (1 mg), -12.9% (4 mg), -17.3% (8 mg) and -17.5% (12 mg) vs -1.6% with placebo. Weight kept falling through week 48.
Limitations
Phase 2: small arms and 48 weeks. Phase 3 results are needed to judge size of effect and safety.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.